Francesco Biroli

Dr. Francesco Biroli

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in World Neurosurgery
Verified
Journal Article
Closed access
PGPaolo Gritti
Paolo Gritti
RZRosalia Zangari
Rosalia Zangari
ACAlessandra Carobbio
Alessandra Carobbio
AZAlberto Zucchi
Alberto Zucchi
FLFerdinando Luca Lorini
Ferdinando Luca Lorini
FBFrancesco Biroli
Francesco Biroli

Verified
Journal Article
Open access
PCPier Luigi Carriero
Pier Luigi Carriero
RZROSALIA ZANGARI
ROSALIA ZANGARI
ESEleonora Sfreddo
Eleonora Sfreddo
AGArianna Ghirardi
Arianna Ghirardi
ASArrigo Schieppati
Arrigo Schieppati
FBFrancesco Biroli
Francesco Biroli
Background: The Angelman Syndrome Registry (RISA) was developed as a retrospective study with the following objectives: to evaluate the clinical history of individuals with Angelman Syndrome (AS) in Italy and compare it with the existing literature; to investigate the feasibility of gathering data by directly involving participants in the data collection process; and to explore the relationship between different symptoms and genotypes. Methods: Established in 2018, RISA enrolled a total of 82 participants, with 62 (75.6%) providing complete data. Demographic, clinical, and genetic information was collected using electronic case report forms. Descriptive statistics characterized the sample, while associations between genotype and clinical characteristics were examined. Results: Descriptive analysis revealed a median participant age of 8.0 years, with males comprising 48.8% of the sample. Deletion (58.1%) was the most common genotype. The majority (82.2%) experienced epilepsy, with seizures typically onset before 3 years of age. Most patients (86.2%) required multiple anti-epileptic drugs for control, with generalized tonic–clonic seizures and atypical absence seizures being most prevalent. The deletion group exhibited more severe developmental delays and a trend towards higher seizure severity. Sleep problems affected 69.4% of participants, characterized by difficulties in sleep onset and maintenance. Conclusions: This study offers valuable insights into the clinical history and genetic characteristics of AS in Italy, consistent with the prior literature. Additionally, it underscores the efficacy of patient registries in capturing comprehensive data on rare diseases such as AS, highlighting their potential to advance research and enhance patient care.

20 November 2025 in Sensors
Verified
Journal Article
Open access
PDF file
RZROSALIA ZANGARI
ROSALIA ZANGARI
LBLaura Brighina
Laura Brighina
APAndrea Pilotto
Andrea Pilotto
GCGreta Carioli
Greta Carioli
Vincenzo D’AgostinoVincenzo D’Agostino
Vincenzo D’Agostino
DADario Alimonti
Dario Alimonti
Gait assessment is key in Parkinson’s disease (PD), but the psychometric properties of common tests like the 6-Minute Walk Test (6MWT) are not fully established. Inertial Measurement Units (IMUs) offer objective gait measures, potentially reducing repeated testing. This study evaluated whether the resampling of the first 2 min of the 6MWT (2’6MWT) reflects full-test performance in 43 early-to-mild PD patients (median age 65) at baseline, 1-year, and 2-year follow-ups. A trunk-mounted IMU recorded distance covered, walking duration, stride length, gait speed, cadence, and symmetry. Analysis focused on participants with complete longitudinal data from a multicenter original cohort of 62. Stride length and gait speed (2’6MWT vs. 6MWT) demonstrated strong correlations (r > 0.98), near-perfect agreement, <5% error, and stability across follow-ups; cadence showed slightly more variability. The analysis of consecutive 2-min intervals of the 6MWT revealed stable stride length and gait speed, with modest decreases in distance and cadence over time. Exploratory associations of 2’6MWT and 6MWT with motor severity and cognitive status were consistent. These results indicate the 2’6MWT is a reliable, time-efficient alternative to the full 6MWT for assessing walking capacity in PD, especially in outpatient or fatigue-prone patients. The full 6MWT remains valuable for detecting subtle endurance- or fatigue-related changes.